Abstract
The clinical and hemodynamic effects of compassionate therapy with levosimendan were evaluated in a 14-year-old patient with end-stage renal disease and arterial hypertension secondary to glycogenosis type Ia. The patient previously had normal heart function but experienced acute development of severe myocardial dysfunction resistant to diuretic therapy and inotropic support. Levosimendan administration was followed by a marked clinical and echocardiographic improvement. The authors believe that levosimendan may be useful for cases of resistant acute heart failure with arterial hypertension. Although administration of levosimendan is not recommended for patients with chronic renal disease, no adverse effect was observed. Therapeutic action for these patients seems to last longer than for patients with a normal kidney.
MeSH terms
-
Acute Disease
-
Adolescent
-
Cardiomyopathy, Dilated / complications*
-
Cardiomyopathy, Dilated / diagnosis
-
Cardiomyopathy, Dilated / physiopathology
-
Cardiotonic Agents / administration & dosage
-
Cardiotonic Agents / therapeutic use
-
Diuresis / drug effects
-
Dose-Response Relationship, Drug
-
Echocardiography, Doppler, Pulsed
-
Follow-Up Studies
-
Glycogen Storage Disease Type I / complications*
-
Glycogen Storage Disease Type I / drug therapy
-
Heart Failure / drug therapy*
-
Heart Failure / etiology
-
Heart Failure / physiopathology
-
Humans
-
Hydrazones / administration & dosage
-
Hydrazones / therapeutic use*
-
Hypertension / complications*
-
Hypertension / diagnosis
-
Hypertension / physiopathology
-
Infusions, Intravenous
-
Kidney Failure, Chronic / complications*
-
Kidney Failure, Chronic / diagnosis
-
Kidney Failure, Chronic / physiopathology
-
Male
-
Myocardial Contraction / drug effects
-
Pyridazines / administration & dosage
-
Pyridazines / therapeutic use*
-
Simendan
-
Stroke Volume / drug effects
Substances
-
Cardiotonic Agents
-
Hydrazones
-
Pyridazines
-
Simendan